
Episode 402: 410. When You Shouldn't Double Down But Instead Hit for Another
16.10.2025
0:00
8:18
This massive meta-analysis of 484 randomized, double-blind, placebo-controlled trials (104,176 participants) quantified the blood pressure–lowering effects of major antihypertensive drug classes and their combinations. It introduces a new intensity-based classification system and an online calculator to predict BP-lowering efficacy based on drug, dose, and baseline BP.
Study Design:
- 484 trials, 104,176 participants
 - 5 major drug classes: ACE inhibitors, ARBs, β-blockers, calcium channel blockers (CCBs), and diuretics
 - Focus: Placebo-corrected reduction in systolic BP (SBP)
 - Mean baseline BP: 154/100 mm Hg
 - Mean follow-up: 8.6 weeks
 
Key Findings
Monotherapy (Standard Dose):
- Average SBP reduction: 8.7 mm Hg
 - 
By class:
- ACE inhibitors: 6.8 mm Hg
 - ARBs: 8.5 mm Hg
 - β-blockers: 8.9 mm Hg
 - CCBs: 9.5 mm Hg
 - Thiazide diuretics: 10.8 mm Hg
 
 
Dose Doubling:
- Adds ~1.5 mm Hg SBP reduction (except β-blockers, which add only ~0.5 mm Hg)
 
Dual Therapy (Standard Dose of Each):
- Average SBP reduction: 14.9 mm Hg
 - Dose doubling adds ~2.5 mm Hg more
 
Triple Therapy:
- SBP reduction: Up to 22.5 mm Hg (quadruple therapy even higher in one trial)
 
Flere episoder fra "Questioning Medicine"



Gå ikke glip af nogen episoder af “Questioning Medicine” - abonnér på podcasten med gratisapp GetPodcast.







